Literature DB >> 35278208

Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.

Fernanda Talarico1,2,3, Giovany Oliveira Costa1,2,4, Vanessa Kiyomi Ota1,2, Marcos Leite Santoro1,2, Cristiano Noto1,4, Ary Gadelha1,4, Rodrigo Bressan1,4, Hatylas Azevedo1,2, Sintia Iole Belangero5,6,7.   

Abstract

Treatment-resistant schizophrenia (TRS) occurs in one-third of the patients, but the molecular determinants of poor antipsychotic response remain unclear. We compared genetic data of patients with TRS (n = 63) with non-TRS (n = 111) by polygenic risk scores (PRS) calculated by PRSice software using PGC2_SCZ (Psychiatric Genomics Consortium - Schizophrenia) data. TRS criteria followed the International Psychopharmacology Algorithm Project SCZ algorithm. Statistical clustering and functional enrichment analyses of genes harboring TRS-linked variants were performed. Individuals on the top three deciles of schizophrenia PRS distribution exhibited higher odds of being refractory to antipsychotics than those on the bottom three deciles. Clusters of interacting variant-harboring genes were identified among the association signals. They are upregulated in the dorsolateral prefrontal, orbitofrontal, temporal, and inferior parietal areas during adolescence and early adulthood. Similar gene modules were found using transcriptional data from the same brain regions in individuals with schizophrenia. Genes were enriched among markers of cortical interneurons and somatosensory pyramidal cells. Finally, the enrichment of the clustered genes in drug-response expression signatures revealed compounds that could be employed to identify novel antipsychotic targets. In conclusion, we identified variant-harboring genes that may predispose SCZ patients to poor antipsychotic response and found statistically enriched clusters which provided functional and spatiotemporal context for TRS, suggesting that genotypic variation may converge to biological alterations at the interplay between actin dynamics and synaptic organization.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antipsychotic response; Genetic markers; Polygenic risk scores; Treatment-resistant schizophrenia

Mesh:

Substances:

Year:  2022        PMID: 35278208     DOI: 10.1007/s12035-022-02794-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  46 in total

Review 1.  Genetics meets proteomics: perspectives for large population-based studies.

Authors:  Karsten Suhre; Mark I McCarthy; Jochen M Schwenk
Journal:  Nat Rev Genet       Date:  2020-08-28       Impact factor: 53.242

Review 2.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis.

Authors:  Dan Siskind; Victor Siskind; Steve Kisely
Journal:  Can J Psychiatry       Date:  2017-06-28       Impact factor: 4.356

Review 3.  Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.

Authors:  Frederick C Nucifora; Edgar Woznica; Brian J Lee; Nicola Cascella; Akira Sawa
Journal:  Neurobiol Dis       Date:  2018-08-29       Impact factor: 5.996

4.  Unravelling the genetic basis of schizophrenia and bipolar disorder with GWAS: A systematic review.

Authors:  Diana P Prata; Bernardo Costa-Neves; Gonçalo Cosme; Evangelos Vassos
Journal:  J Psychiatr Res       Date:  2019-04-12       Impact factor: 4.791

5.  Gene expression elucidates functional impact of polygenic risk for schizophrenia.

Authors:  Menachem Fromer; Panos Roussos; Solveig K Sieberts; Jessica S Johnson; David H Kavanagh; Thanneer M Perumal; Douglas M Ruderfer; Edwin C Oh; Aaron Topol; Hardik R Shah; Lambertus L Klei; Robin Kramer; Dalila Pinto; Zeynep H Gümüş; A Ercument Cicek; Kristen K Dang; Andrew Browne; Cong Lu; Lu Xie; Ben Readhead; Eli A Stahl; Jianqiu Xiao; Mahsa Parvizi; Tymor Hamamsy; John F Fullard; Ying-Chih Wang; Milind C Mahajan; Jonathan M J Derry; Joel T Dudley; Scott E Hemby; Benjamin A Logsdon; Konrad Talbot; Towfique Raj; David A Bennett; Philip L De Jager; Jun Zhu; Bin Zhang; Patrick F Sullivan; Andrew Chess; Shaun M Purcell; Leslie A Shinobu; Lara M Mangravite; Hiroyoshi Toyoshiba; Raquel E Gur; Chang-Gyu Hahn; David A Lewis; Vahram Haroutunian; Mette A Peters; Barbara K Lipska; Joseph D Buxbaum; Eric E Schadt; Keisuke Hirai; Kathryn Roeder; Kristen J Brennand; Nicholas Katsanis; Enrico Domenici; Bernie Devlin; Pamela Sklar
Journal:  Nat Neurosci       Date:  2016-09-26       Impact factor: 24.884

6.  Indicated association between polygenic risk score and treatment-resistance in a naturalistic sample of patients with schizophrenia spectrum disorders.

Authors:  Maren Caroline Frogner Werner; Katrine Verena Wirgenes; Marit Haram; Francesco Bettella; Synve Hoffart Lunding; Linn Rødevand; Gabriela Hjell; Ingrid Agartz; Srdjan Djurovic; Ingrid Melle; Ole A Andreassen; Nils Eiel Steen
Journal:  Schizophr Res       Date:  2020-03-11       Impact factor: 4.939

Review 7.  Treatment-Resistant Schizophrenia.

Authors:  Helio Elkis; Peter F Buckley
Journal:  Psychiatr Clin North Am       Date:  2016-03-30

8.  Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia.

Authors:  Theresa Wimberley; Christiane Gasse; Sandra Melanie Meier; Esben Agerbo; James H MacCabe; Henriette Thisted Horsdal
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

Review 9.  Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review.

Authors:  Amy L Gillespie; Ruta Samanaite; Jonathan Mill; Alice Egerton; James H MacCabe
Journal:  BMC Psychiatry       Date:  2017-01-13       Impact factor: 3.630

Review 10.  Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology.

Authors:  Oliver D Howes; Rob McCutcheon; Ofer Agid; Andrea de Bartolomeis; Nico J M van Beveren; Michael L Birnbaum; Michael A P Bloomfield; Rodrigo A Bressan; Robert W Buchanan; William T Carpenter; David J Castle; Leslie Citrome; Zafiris J Daskalakis; Michael Davidson; Richard J Drake; Serdar Dursun; Bjørn H Ebdrup; Helio Elkis; Peter Falkai; W Wolfgang Fleischacker; Ary Gadelha; Fiona Gaughran; Birte Y Glenthøj; Ariel Graff-Guerrero; Jaime E C Hallak; William G Honer; James Kennedy; Bruce J Kinon; Stephen M Lawrie; Jimmy Lee; F Markus Leweke; James H MacCabe; Carolyn B McNabb; Herbert Meltzer; Hans-Jürgen Möller; Shinchiro Nakajima; Christos Pantelis; Tiago Reis Marques; Gary Remington; Susan L Rossell; Bruce R Russell; Cynthia O Siu; Takefumi Suzuki; Iris E Sommer; David Taylor; Neil Thomas; Alp Üçok; Daniel Umbricht; James T R Walters; John Kane; Christoph U Correll
Journal:  Am J Psychiatry       Date:  2016-12-06       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.